All In Biotech

Drug Trial Radar · NCT04292314

Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia

Impact of Combination Therapy Between Hydroxy Urea, Omega 3, Nigella Sativa and Honey on Antioxidant-oxidant Status and Reduction of Iron Overload in Pediatric Major Thalassemia

Last checked: Nov 19, 2026Latest source record: Jan 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

350

Actual

Start

Nov 1, 2019

Primary completion

Dec 20, 2020

Study completion Jan 20, 2021

Sponsor

Lead sponsor
Beni-Suef UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Maternity and Children Hospital, Makkah; Beni-Suef Health insurance hospital; University of Arizona
First posted
Mar 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 7 years, up to 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the present study is evaluating the strength of combination therapy of hydroxy urea, omega 3, nigella sativa and honey on antioxidant-oxidant status (OXIDATIVE STRESS) in response to reactive oxygen species production (LIPID PEROXIDATION) and their effect on iron intoxication (IRON CHELATION) in pediatric major thalassemia.

Conditions

  • Iron Overload
  • Oxidative Stress
  • Thalassemia Major

Interventions

  • Omega 3Drug

    Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months

  • Nigella Sativa OilDrug

    Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months

  • HydroxyureaDrug

    hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.

  • HoneyDrug

    Natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.

  • DeferoxamineDrug

    deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.

  • blood transfusion sessionProcedure

    Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. F 2 -isoprostanes pg/mLTime frame: 3 months
  2. Total cholesterol Mg/dlTime frame: 10 months
  3. HDL cholesterol Mg/dlTime frame: 10 months
  4. LDL cholesterol Mg/dlTime frame: 10 months
  5. Triglycerides Mg/dlTime frame: 10 months
  6. Serum total iron mcg/dLTime frame: 10 months
  7. % transferrin saturationTime frame: 10 months
  8. C-reactive protein mg/LTime frame: 10 months
  9. Serum Ferritin ng/mlTime frame: 10 months
  10. Total Iron Binding Capacity (TIBC) mcg/dLTime frame: 10 months
  11. hemoglobin (Hbg) g/dLTime frame: 10 months
  12. mean corpuscular hemoglobin (MCH) pg/mlTime frame: 10 months
  13. leukocytes count μlTime frame: 10 months
  14. % Chelation activity Fe+++ - thymoquinone complexTime frame: 3 months
  15. % Chelation activity Fe++ - thymoquinone complexTime frame: 3 months
  16. Lactic acid dehydrogenase U/LTime frame: 10 months
  17. Reticulocyte count %Time frame: 10 months
  18. Hb-F level g/dLTime frame: 10 months
  19. Reticulocyte absolute countTime frame: 10 months
  20. White blood cells countTime frame: 10 months

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Faculty of medicine, Beni-suef univeristy - Beni-Suef university hospital

    Banī Suwayf, Egypt

  • Faculty of Pharmacy, Beni-Suef university

    Banī Suwayf, Egypt

  • Health insurance hospital

    Banī Suwayf, Egypt

  • Maternity and Children hospital

    Mecca, Saudi Arabia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.